MoonLake Immunotherapeuti Book Value Per Share vs. Total Debt

MLTX Stock  USD 53.85  1.10  2.09%   
Considering the key profitability indicators obtained from MoonLake Immunotherapeuti's historical financial statements, MoonLake Immunotherapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess MoonLake Immunotherapeuti's ability to earn profits and add value for shareholders.
 
Book Value Per Share  
First Reported
2010-12-31
Previous Quarter
10.45326813
Current Value
10.98
Quarterly Volatility
2.99213137
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, MoonLake Immunotherapeuti's Ebt Per Ebit is fairly stable compared to the past year. Quick Ratio is likely to rise to 54.17 in 2024, whereas Free Cash Flow Yield is likely to drop (0.02) in 2024.
For MoonLake Immunotherapeuti profitability analysis, we use financial ratios and fundamental drivers that measure the ability of MoonLake Immunotherapeuti to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well MoonLake Immunotherapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between MoonLake Immunotherapeuti's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of MoonLake Immunotherapeutics over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MoonLake Immunotherapeuti. If investors know MoonLake will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MoonLake Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.27)
Return On Assets
(0.13)
Return On Equity
(0.17)
The market value of MoonLake Immunotherapeuti is measured differently than its book value, which is the value of MoonLake that is recorded on the company's balance sheet. Investors also form their own opinion of MoonLake Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is MoonLake Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MoonLake Immunotherapeuti's market value can be influenced by many factors that don't directly affect MoonLake Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MoonLake Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine if MoonLake Immunotherapeuti is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MoonLake Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

MoonLake Immunotherapeuti Total Debt vs. Book Value Per Share Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining MoonLake Immunotherapeuti's current stock value. Our valuation model uses many indicators to compare MoonLake Immunotherapeuti value to that of its competitors to determine the firm's financial worth.
MoonLake Immunotherapeutics is rated below average in book value per share category among its peers. It is rated below average in total debt category among its peers making up about  491,556  of Total Debt per Book Value Per Share. At this time, MoonLake Immunotherapeuti's Book Value Per Share is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the MoonLake Immunotherapeuti's earnings, one of the primary drivers of an investment's value.

MoonLake Total Debt vs. Book Value Per Share

Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

MoonLake Immunotherapeuti

Book Value per Share

 = 

Common Equity

Average Shares

 = 
7.74 X
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

MoonLake Immunotherapeuti

Total Debt

 = 

Bonds

+

Notes

 = 
3.81 M
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

MoonLake Total Debt vs Competition

MoonLake Immunotherapeutics is rated below average in total debt category among its peers. Total debt of Health Care industry is now estimated at about 1.14 Billion. MoonLake Immunotherapeuti adds roughly 3.81 Million in total debt claiming only tiny portion of equities under Health Care industry.
Total debt  Workforce  Capitalization  Valuation  Revenue

MoonLake Immunotherapeuti Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in MoonLake Immunotherapeuti, profitability is also one of the essential criteria for including it into their portfolios because, without profit, MoonLake Immunotherapeuti will eventually generate negative long term returns. The profitability progress is the general direction of MoonLake Immunotherapeuti's change in net profit over the period of time. It can combine multiple indicators of MoonLake Immunotherapeuti, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income2.4 M2.5 M
Operating Income-54.1 M-51.4 M
Income Before Tax-44 M-46.2 M
Total Other Income Expense Net10.1 M10.6 M
Net Loss-44.1 M-46.3 M
Income Tax Expense94.4 K99.1 K
Net Loss-52.7 M-55.3 M
Non Operating Income Net Other680.5 K340.7 K
Net Loss-45 M-42.7 M
Change To Netincome11.2 M11.7 M
Net Loss(0.73)(0.77)
Income Quality 0.97  1.64 
Net Income Per E B T 0.82  1.03 

MoonLake Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on MoonLake Immunotherapeuti. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of MoonLake Immunotherapeuti position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the MoonLake Immunotherapeuti's important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in MoonLake Immunotherapeuti without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Technical Analysis Now

   

Technical Analysis

Check basic technical indicators and analysis based on most latest market data
All  Next Launch Module

Use Investing Themes to Complement your MoonLake Immunotherapeuti position

In addition to having MoonLake Immunotherapeuti in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Financials ETFs Thematic Idea Now

Financials ETFs
Financials ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Financials ETFs theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Financials ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for MoonLake Stock Analysis

When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.